Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer - Test2 - elhamkhani - TriplyDB

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

http://www.wikidata.org/entity/Q34223171

about

Evidence-based management of incidental focal uptake of fluorodeoxyglucose on PET-CT.PET/CT incidental detection of second tumor in patients investigated for pancreatic neoplasms.

P2860

Q48111912-08C1AC52-6C35-4F84-9E91-91D273A20B8B Q55279829-A691C701-AB2F-4A26-BE3C-AAB03182C7B5

P2860

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

http://www.wikidata.org/entity/Q34223171

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@ast

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@en

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@nl

type

label

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@ast

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@en

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@nl

prefLabel

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@ast

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@en

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@nl

P1433

Q34223171-BE5FF072-CB49-4B4A-9E01-623EB3624572

P1476

Q34223171-B84AF692-1EAD-43F7-960E-16974513D604

P2093

Q34223171-0BDED43C-88C1-4F6F-B604-FE700CB4BC63

Q34223171-155BC075-D0C9-4A4E-8AE4-E5AA71989DAD

Q34223171-5B5F2A25-5B2C-46F8-8BC9-A52FEF5DC363

Q34223171-855F4AFA-367B-4F9B-9A20-A688128D7CFA

Q34223171-F1CECD7A-9C18-4976-9507-C3271192C88F

P2860

Q34223171-359805C9-8FF3-4DD9-B483-D44F3FB0DAE6

Q34223171-368F2A9A-DBEE-4431-8B53-9D28AA6C2B03

Q34223171-39CEABDF-4C71-480E-AAA4-ECEA76E27F0F

Q34223171-3CD39A27-397E-491A-B8B6-885E0A62108C

Q34223171-3DFE75DC-9AA6-4C21-B38F-DBEAA2335C8F

Q34223171-57F91A16-8183-43BE-9895-AB7BC40D09B1

Q34223171-5E41C4AE-17AD-4A2A-B935-C326E10AD458

Q34223171-68F1810D-85CA-4AE8-B3D8-992B3C23BC40

Q34223171-6EA5ECF8-652B-4338-B88B-B2374CAE39CD

Q34223171-6EEC52C4-5779-4106-B648-25A3DC46DFD5

P304

Q34223171-1D0A40B1-835B-44D7-87AB-3CE2B7A2F6D8

P31

Q34223171-BF62B820-FDE1-4BC7-9731-A2A21E5A19A6

P356

Q34223171-0BAE811F-0ADC-4422-B94B-6183F30247FC

P407

Q34223171-876386CF-593E-46B5-B45A-82FEF249E806

P433

Q34223171-E10187A8-4B80-4038-9405-0556D2E353C9

P478

Q34223171-08CE9C10-288F-4076-AF0D-00C02D198CC5

P50

Q34223171-BEDF399A-71A6-4650-A33F-1D3FC3A0A45D

P577

Q34223171-5138C032-BE67-4297-8861-5090F50A0642

P5875

Q34223171-C2A68531-361B-4639-B239-FD109CEBAC73

P698

Q34223171-D2A61E14-DC1E-4527-BAAA-C5E3AA1CF43F

P932

Q34223171-9BB783D3-571D-4657-BF64-F5517B52530A

P356

P1433

British Journal of Radiology

P1476

Ability of 18-fludeoxyglucose positron emission tomography/CT to detect incidental cancer

@en

P2093

A Sobajima

http://www.w3.org/2001/XMLSchema#string

K Kato

http://www.w3.org/2001/XMLSchema#string

S Kohara

http://www.w3.org/2001/XMLSchema#string

T Kawachi

http://www.w3.org/2001/XMLSchema#string

Y Sone

http://www.w3.org/2001/XMLSchema#string

P2860

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.

The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey

Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.

Clinical applications of PET in oncology.

How do oncologists deal with incidental abnormalities on whole-body fluorine-18 fluorodeoxyglucose PET/CT?

False-positive uptake on 2-[¹⁸F]-fluoro-2-deoxy-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in oncological imaging.

Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma.

The clinical significance of 18F-FDG-PET/CT in early detection of second primary malignancy in cancer patients.

Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison.

P304

20140030

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1259/BJR.20140030

http://www.w3.org/2001/XMLSchema#string

P407

P433

1042

http://www.w3.org/2001/XMLSchema#string

P478

87

http://www.w3.org/2001/XMLSchema#string

P50

Shinji Naganawa

P577

2014-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264796531

http://www.w3.org/2001/XMLSchema#string

P698

25117626

http://www.w3.org/2001/XMLSchema#string

P932

4170860

http://www.w3.org/2001/XMLSchema#string